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A B S T R A C T
Introduction: The causes of pain in early/moderate Parkinson's disease (PD) are not well understood. Although
peripheral factors such as rigidity, reduced joint movements and poor posture may contribute towards the de-
velopment of pain, central mechanisms including altered nociceptive processing may also be involved.
Methods: We performed a large clinical study to investigate potential factors contributing towards pain in early/
moderate PD. We recruited 1957 PD participants who had detailed assessments of pain, motor and non-motor
symptoms. The King's Parkinson's Pain scale was used to quantify different subtypes of pain.
Results: 85% of participants reported pain (42% with moderate to severe pain). Pain influenced quality of life
more than motor symptoms in a multiple regression model. Factors predicting overall pain severity included
affective symptoms, autonomic symptoms, motor complications, female gender and younger age, but not motor
impairment or disease duration. There was negligible correlation between the severity of motor impairment and
the severity of musculoskeletal or dystonic pain as well as between the severity of OFF period motor problems
and the severity of OFF period pain or OFF period dystonic pain. Features of central sensitization, including
allodynia and altered pain sensation were common in this population. The use of drugs targeting central pain
was very low.
Conclusions: Pain in early/moderate PD cannot be explained by peripheral factors. Central causes may play a
much more important role than previously considered. These results should lead to a major shift in the in-
vestigation and management of this common and disabling symptom.
1. Introduction
Chronic pain affects 60–80% of Parkinson's disease (PD) patients
and is often a disabling symptom [1–3]. In the widely used Ford clas-
sification, the most common subtypes of PD pain are musculoskeletal,
radicular and dystonic [4]. Central pain is thought to be fairly un-
common in PD [1,2,4]. Pain in PD may be a direct consequence of other
disease-related symptoms: mobility problems, including stiffness, re-
duced joint movements and poor posture are felt to be the main cause of
musculoskeletal pain and radicular pain; OFF-period mobility problems
and dystonic contractions are thought to be the main cause of OFF-
period pain [4,5].
While chronic pain can be caused by peripheral tissue damage, an
alternative mechanism is dysfunction of pain regulatory systems within
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the brain, leading to amplification of the pain signal (central sensiti-
zation). It is increasingly recognised that many if not most cases of
chronic pain are due to altered nociceptive processing within the cen-
tral nervous system [6,7].
There are several potential mechanisms that may lead to enhanced
central processing of pain signals in PD. The dopaminergic pathway
from the ventral tegmental area to the nucleus accumbens is an im-
portant anti-nociceptive pathway, which degenerates in PD [8]. Fur-
thermore brainstem serotonergic and norepinephrinergic neurons de-
generate prior to the onset of motor symptoms in PD [9,10].
Degeneration of these neurons is proposed to be a cause of affective and
autonomic symptoms in PD [10]. However these neurons are also the
source of powerful ascending and descending anti-nociceptive path-
ways and their degeneration would therefore be predicted to cause
central sensitization of pain signals [11]. Indeed many analgesic drugs,
including duloxetine and amitriptyline act through enhancing trans-
mission in these pathways [12]. Reduced pain thresholds [13], altered
pain evoked electrical responses [14] and increased pain evoked cor-
tical network activation [15,16], all provide evidence that altered
central processing of pain may be an important contributing factor
towards pain in PD.
We had several objectives in this study:
1) We hypothesised that pain is an important symptom leading to
impaired quality of life in PD. We compared the contribution of pain
and motor symptoms in determining quality of life in a large po-
pulation of participants with relatively early stage PD.
2) We hypothesised that a large detailed clinical study would help us to
understand the causes as well as the potential treatments of pain in
PD. We used the King's Parkinson's Pain scale to classify and quan-
tify PD pain into different subtypes [17]. We investigated whether
the severity of other disease-related symptoms correlated with the
severity of the pain subtypes felt to be caused by these symptoms,
including whether or not the severity of mobility problems corre-
lated with the severity of musculoskeletal and radicular pain. We
also investigated for symptoms suggesting centrally-generated pain
including cutaneous allodynia.
3) We hypothesised that pain frequency and severity in PD would
correlate with the severity of other symptoms attributable to ser-
otonergic and norepinephrinergic depletion, including anxiety, de-
pression and autonomic dysfunction.
2. Methods
2.1. Ethical approval
The study was carried out in accordance with the Declaration of
Helsinki and authorized by a UK ethics committee (National Research
Ethics Service Committee North West – Preston). All patients gave
written consent prior to any study procedures.
2.2. Participants
Participants were recruited from 68 centres throughout the UK. All
participants were recruited from one of two large UK multi-centre
longitudinal epidemiological and biomarker studies in PD, those being
the Tracking Parkinson's study [18] and the Oxford Monument Dis-
covery Study [19]. The inclusion and exclusion criteria for these other
studies have been previously published [18,19]. The pain study was a
sub-study of these other studies using the same research nurses, al-
though it was funded and run separately. It was performed at a single
occasion at any one of the main study visits.
2.3. Pain assessments
Pain was assessed using the Short Form McGill Pain Questionnaire
(SFMPQ) [20], Visual Analogue Scale (VAS) for pain severity over the
last month and the recently validated Kings Parkinson's Pain Scale
(KPPS) [17]. Participants scoring>0 on the SFMPQ were defined as
having pain. Similar to previous large pain studies, participants scoring
5 or more on the VAS for pain severity over the last month were defined
as having moderate to severe pain [21]. For those with more than 1
type of pain, the most troublesome pain was used to record the SFMPQ
and VAS ratings.
The King's Parkinson's Pain Scale quantifies pain across different
subtypes. For each subtype the participant rates severity (0–3) and
frequency (0–4). The frequency and severity are multiplied together to
create a total score for that subtype of pain. The subtypes include
musculoskeletal pain (pain around the joints), radicular pain (shooting
pain down the limbs), dystonic pain (OFF period pain in a region of
dystonia), generalised OFF period pain, lower abdominal pain, visceral
pain (pain related to an internal organ such as liver, stomach or bo-
wels), restless leg syndrome (RLS) and central pain (a generalised
constant dull aching pain).
2.4. Other assessments
Detailed analysis of motor and non-motor symptoms using validated
scales was performed to document whether or not the severity of dif-
ferent pain types could be explained by the severity of other motor and
non-motor symptoms. The analysis included the Movement Disorder
Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III
to document the motor impairment severity, MDS-UPDRS Part IV to
document the severity of motor fluctuations, the Leeds Anxiety and
Depression Scale (LADS) anxiety score (LADS-A) and depression score
(LADS-D) [22] the Scales for Outcomes in Parkinson's disease – Auto-
nomic Symptoms (SCOPA-AUT) to document the severity of autonomic
symptoms, the Montreal Cognitive Assessment (MoCA) and the EQ-5D
index, a measure of quality of life (QoL).
The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS)
scale was used to document the presence of neuropathic pain [23]. The
LANSS scale is validated to detect neuropathic pain and uses an as-
sessment of sensory function (cutaneous allodynia and altered pinprick
threshold over the painful area) as well as pain descriptors to classify
pain which is likely to be centrally generated. Participants were asked
whether the pain was better in the ON state, the OFF state or no dif-
ferent. They were also asked which if any of their ‘non Parkinson's
medications' improved pain. However we did not collect detailed in-
formation regarding which pain medications were being taken at the
time of assessment.
All scales were performed in at least 1600 of the participants with
the exception of the SCOPA-AUT, which was not part of the Oxford
Monument Discovery study therefore was only performed in 816 par-
ticipants. All scales were performed within 6 months of each other.
Thus the motor and non-motor assessments (MDS-UPDRS, LADS, EQ-
5D, SCOPA and MoCA) were all done at the same time. The pain as-
sessments (SFMPQ, VAS, LANSS and KPPS) were all done at the same
time. In 917 participants the pain assessments were done at the same
time as the motor and non-motor assessments. In 527 the pain assess-
ments were done within 6 months after the motor and non-motor as-
sessments. In 513 participants, the pain assessments were done within 6
months before the motor and non-motor assessments. All scales and
assessments were performed in the ON state. In the Tracking
Parkinson's and Oxford Discovery studies, all participants had the MDS-
UPDRS III performed in the OFF state (after 12 h withdrawal of anti-
parkinsonian medication) at a single visit. However in many cases the
pain assessments were done more than 6 months from the MDS-UPDRS-
III OFF so we included MDS-UPDRS-III OFF data only in the 491 par-
ticipants in whom MDS-UPDRS-III OFF was done within 6 months of
the pain assessments.
M.A. Silverdale et al. Parkinsonism and Related Disorders 56 (2018) 27–32
28
2.5. Statistical analysis
Statistical analysis was performed using SPSS (version 22, IBM).
Multiple linear regression analysis was used to investigate factors pre-
dicting quality of life (EQ-5D index) in PD. Predictor variables in the
model included severity of pain (SFMPQ), severity of motor impairment
(MDS-UPDRS-III) and severity of motor complications (MDS-UPDRS-
IV).
Multiple linear regression analysis was used to investigate factors
predicting the overall severity of pain (SFMPQ) in PD. Candidate
variables in the model were MDS-UPDRS-III, MDS-UPDRS-IV, SCOPA-
AUT, LADS, MoCA, age, disease duration and female gender.
Correlation analysis was used to investigate the relationship be-
tween different types of pain (as measured with the Kings Parkinson's
Pain Scale) and other disease related factors. Due to the non-parametric
nature of the individual scales, in particular those in the King's
Parkinson's Pain Scale, non-parametric (Spearman's rank) correlation
analysis was used.
3. Results
3.1. Study population and pain characteristics
1957 participants were recruited into the UK Parkinson's Pain
Study. 65% were male. Table 1 shows the characteristics of the study
population. This was a population with relatively early PD. 1648 out of
1944 participants recording SFMPQ (85%) reported pain at the time of
assessment. 808 participants (42%) reported moderate to severe pain.
The main pain subtypes were: musculoskeletal pain (66% of those with
pain), radicular pain (34%), dystonic pain (16%), generalised OFF pain
(9%), dyskinetic pain (10%), lower abdominal pain (16%), visceral pain
(16%), central pain (27%) and restless leg syndrome (23%). 395 par-
ticipants reported 1 type of pain, 389 reported 2 types, 281 reported 3
types and the rest reported 4 or more types of pain.
3.2. Effects of pain and motor symptoms on quality of life
Predictors of quality of life (EQ-5D index) in the regression model
(Table 2) were motor examination (MDS-UPDRS III), motor complica-
tions (MDS-UPDRS IV) and pain (SFMPQ). The model accounted for
26% of the variance in quality of life. In this population of participants
with fairly early PD, all of the variables had an effect on quality of life
and the effect of pain was higher than that of motor disability or motor
fluctuations.
3.3. Central mechanisms and pain
33% of those with pain had evidence for altered sensory processing
over the painful area, this being either cutaneous allodynia, altered
pinprick threshold or both. 10% of participants with pain had a LANSS
score of ≥12 indicating the presence of neuropathic pain [23].
3.4. Factors predicting pain in PD
Table 3 shows the results of a regression analysis using the overall
severity of pain (SFMPQ) as the outcome variable and the severity of
other disease related symptoms as predictor variables. The model ex-
plained 21% of the overall variance in pain severity. Factors having a
statistically significant effect on pain severity were motor complica-
tions, autonomic symptoms, affective symptoms, younger age and fe-
male gender. The severity of motor impairment and the severity of
cognitive impairment did not have a statistically significant effect on
the severity of pain.
3.5. Medications and pain in PD
Pain was reported to be worse in the OFF state by 17% of partici-
pants, whereas 2% felt it was worse in the ON state and 81% felt there
was no difference between the ON and OFF state with regards to pain
Table 1
Characteristics of the study population.
Mean SD n
Age (Year) 68 9.5 1914
Disease Duration (Years) 3.0 2.1 1887
LADS-Anxiety 4.1 3.6 1737
LADS-Depression 4.5 3.2 1729
MDS-UPDRS-III 27 13.6 1657
MDS-UPDRS-III (OFF) 33.5 15.5 495
MDS-UPDRS-IV 1.2 2.4 1685
SCOPA-AUT 12.5 7.2 823
MoCA 25.1 3.6 1706
SFMPQ 6.8 6.6 1944
EQ-5D Index 0.71 0.24 1751
SD, standard deviation; LADS-Anxiety, Leeds Anxiety and Depression Scale-
Anxiety; LADS-Depression, Leeds Anxiety and Depression Scale-Depression;
MDS-UPDRS-III, Unified Parkinson's disease Rating Scale Part III (motor ex-
amination); MDS-UPDRS-IV, Unified Parkinson's disease Rating Scale Part IV
(motor complications); SCOPA-AUT, the Scales for Outcomes in Parkinson's
disease – Autonomic Symptoms. MoCA, Montreal Cognitive Assessment;
SFMPQ, Short Form McGill Pain Questionnaire; EQ-5D Index, Quality of Life
Scale.
Table 2
Multiple linear regression for health-related Quality of life (EQ-5D Index).
R2 Beta T 95% Confidence intervals sig
Lower upper
0.26
MDS-UPDRS-
III
−0.003 −8.4 −0.004 −0.003 < 0.001
MDS-UPDRS-
IV
−0.016 −7.1 −0.021 −0.012 < 0.001
SFMPQ −0.014 −16.6 −0.015 −0.012 < 0.001
MDS-UPDRS-III, Unified Parkinson's disease Rating Scale Part III (motor ex-
amination); MDS-UPDRS-IV, Unified Parkinson's disease Rating Scale Part IV
(motor complications); SFMPQ, Short Form McGill Pain Questionnaire.
Table 3
Multiple linear regression for pain severity - Short form McGill Pain
Questionnaire (SFMPQ).
R2 Beta t 95% Confidence
intervals
sig
lower upper
0.21
MDS-UPDRS-
III
0.003 0.185 −0.031 0.038 0.853
MDS-UPDRS-
IV
0.213 2.121 0.016 0.411 0.034
SCOPA 0.224 6.031 0.151 0.297 < 0.001
LADS 0.224 5.347 0.142 0.307 < 0.001
MoCA −0.005 −0.076 −0.135 0.125 0.940
Age −0.072 −2.801 −0.123 −0.022 0.005
Disease
Duration
0.071 0.676 −0.136 0.278 0.394
Gender
(Female)
1.619 3.450 0.698 2.540 0.001
MDS-UPDRS-III, Unified Parkinson's disease Rating Scale Part III (motor ex-
amination); MDS-UPDRS-IV, Unified Parkinson's disease Rating Scale Part IV
(motor complications); SCOPA-AUT, the Scales for Outcomes in Parkinson's
disease – Autonomic Symptoms; LADS, Leeds Anxiety and Depression Scale;
MoCA, Montreal Cognitive Assessment.
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severity. Regarding medications which were being used to treat pain
and which were felt by the participant to be effective for PD pain, 28%
of those with pain reported benefit from paracetamol (acetaminophen),
compared to 12% from non steroidal anti-inflammatory drugs (NSAIDS)
and 10% from using opioids. Only 3% of participants with pain derived
benefit from drugs targeting central pain mechanisms, including ga-
bapentin, pregabalin, duloxetine and amitriptyline.
3.6. Correlation between individual subtypes of pain and other disease
related symptoms
Table 4 shows the correlation between different types of pain (as
measured with the King's Parkinson's pain scale) and other disease-re-
lated symptoms. There was negligible correlation between the severity
of musculoskeletal pain and the severity of motor symptoms (MDS-
UPDRS III) in both the ON and OFF states. There was weak correlation
between the severity of musculoskeletal pain and the severity of motor
complications (MDS-UPDRS-IV), autonomic symptoms (SCOPA-AUT),
anxiety (LADS-A) and depression (LADS-D).
Similarly there was negligible correlation between radicular pain
severity and the severity of motor symptoms. There was only weak
correlation with the severity of motor complications, autonomic
symptoms, anxiety and depression.
There was poor correlation between the severity of OFF period
motor problems as measured with MDS-UPDRS-III OFF and the severity
of either dystonic OFF pain or generalised OFF pain. OFF period pain
was significantly correlated with MDS-UPDRS-IV but the correlation
was only weak. Dyskinetic pain correlated with the severity of motor
fluctuations, although only with a very weak association. Both lower
abdominal pain and visceral pain correlated with constipation scores
(Q1.11 in MDS-UPDRS). However the association was only weak. Both
of these types of pain correlated with autonomic symptoms, again only
with a weak association.
4. Discussion
4.1. Influence of pain on quality of life in PD
Our first hypothesis was that pain is an important symptom leading
to impaired quality of life in PD. In our study, pain was extremely
common in this large population of participants at a relatively early
stage of PD. 85% of participants reported pain and 42% of participants
reported moderate to severe pain. Although we did not have a control
group, the frequency of pain is clearly much higher than previously
reported in the general population. A European study of 46,394 parti-
cipants, using similar inclusion criteria and definitions of pain severity
to our study, noted a prevalence of moderate to severe pain of 19%,
although the figure was 13% if only the 3800 UK participants were
included [21]. Our results therefore confirm previous studies indicating
a very high prevalence of pain in PD [1,2].
In our study pain had an effect on quality of life, which was greater
than motor impairment and comparable to the effect of motor com-
plications. Other smaller studies have reported similar findings [24].
Given the amount of research that has gone into understanding mobility
problems in PD, it is clear that there needs to be more research into
understanding the causes of pain in PD with a view to developing im-
proved treatments.
It should be highlighted that participants in our study had fairly
mild motor impairment/complications and results may be different in a
more severely-affected population.
4.2. Relationship between pain and other disease symptoms
Our second hypothesis was that a large and detailed clinical study
would help us to understand the causes and therefore identify potential
treatments for pain in PD. The severity of motor impairment did not
predict the overall severity of pain (SFMPQ). Furthermore the severity
of motor fluctuations only weakly predicted variance in the severity of
pain. Thus mobility issues are probably not a very important cause for
the markedly increased frequency and severity of pain in PD.
The size and scope of our study enabled us for the first time, to
perform an analysis of the factors which may be contributing towards
different subtypes of pain in PD. Musculoskeletal pain and radicular
pain are the most common types of pain in PD. We saw negligible
correlation between these pain subtypes and MDS-UPDRS-III, sug-
gesting that mobility factors are not an important cause. Off period
dystonic pain is common in PD and is understandably attributed to
painful dystonic muscle contractions despite the fact that with one or
two exceptions, dystonia is usually not a painful condition. It is very
interesting therefore that there was negligible correlation between the
severity of dystonic pain and the severity of the MDS-UPDRS-III OFF
motor scores. Similarly there was negligible correlation between gen-
eralised OFF period pain and MDS-UPDRS-OFF scores. Dyskinetic pain
was only weakly correlated with motor fluctuation scores (MDS-
UPDRS-IV). Abdominal pain and visceral pain correlated with con-
stipation severity but with only a small effect size.
Our results suggest that peripheral factors are not an important
cause of these different subtypes of pain in PD. Although we attempted
to analyse peripheral factors in detail, we cannot exclude the possibility
that others which could have contributed to pain were not adequately
assessed in our study. However the high prevalence of either cutaneous
allodynia or altered pinprick threshold over the painful area suggests
that central mechanisms may be a more important contributing factor
towards pain than previously considered. Indeed the LANSS scale
classified 10% of participants as having centrally-generated neuro-
pathic pain. It is well recognised that there is a very poor correlation
between the severity of osteoarthritic problems on imaging and pain
severity [25]. In PD patients with what is described to be
Table 4
Correlation between the severity of individual subtypes of pain and other disease related symptoms.
Musculoskeletal Radicular OFF dystonic General OFF Dyskinetic Lower Abdo Visceral
MDS-UPDRS-III 0.03 0.05 0.02 0.05∗ −0.01 0.04 0.05∗
MDS-UPDRS-III (OFF) 0.04 0.08 0.11∗ 0.06 0.06 0.09∗ 0.07
UPDRS-IV 0.11∗∗ 0.12∗∗ 0.27∗∗ 0.20∗∗ 0.15∗∗ 0.05∗ 0.05∗
LADS-A 0.2∗∗ 0.22∗∗ 0.17∗∗ 0.19∗∗ 0.17∗∗ 0.14∗∗ 0.13∗∗
LADS-D 0.16∗∗ 0.18∗∗ 0.16∗∗ 0.17∗∗ 0.11∗∗ 0.14∗∗ 0.12∗∗
SCOPA-AUT 0.17∗∗ 0.14∗∗ 0.13∗∗ 0.17∗∗ 0.12∗ 0.19∗∗ 0.24∗∗
Constipation 0.10∗∗ 0.06∗ 0.05∗ 0.09∗∗ 0.04 0.17∗∗ 0.16∗∗
Spearman's rank correlation coefficient (rho); ∗P < 0.05; **P < 0.001.
Individual pain subtypes were quantified using the King's Parkinson's Pain Scale.
MDS-UPDRS-III, Unified Parkinson's disease Rating Scale Part III (motor examination); MDS-UPDRS-III (OFF), UPDRS-III after 12 h medication withdrawal; MDS-
UPDRS-IV, Unified Parkinson's disease Rating Scale Part IV (motor complications); SCOPA-AUT, the Scales for Outcomes in Parkinson's disease – Autonomic
Symptoms; LADS-A, Leeds Anxiety and Depression Scale-Anxiety; LADS-D, Leeds Anxiety and Depression Scale-Depression; Constipation, UPDRS 1.11.
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musculoskeletal shoulder problems, there is enhanced sensory proces-
sing over the painful shoulder implicating a role for central factors in
contributing towards musculoskeletal pain in PD [26].
Despite the lack of detailed data on analgesic use, it is noteworthy
that only a very small proportion of participants were using drugs
which target central mechanisms. Our results suggest that more wide-
spread use of these medications should be considered as a treatment for
pain in PD.
Our study data confirms previous reports that female sex is a con-
tributing factor towards pain in PD [1]. Interestingly, age was inversely
associated with pain severity. The relationship between pain and age is
complex, although similar findings have previously been reported in the
general population [27]. Pain due to PD has been linked to younger age
and age at onset [2]. Pain was not associated with disease duration in
our study, although the predominance of fairly early PD participants in
our study precludes too much importance being given to this finding.
We acknowledge study limitations which could have affected these
correlations. The population was of early/moderate PD and results may
be different in more severely-affected participants. There was a delay of
up to 6 months between pain and motor assessments which could have
affected correlations. We did not assess in detail the potential con-
founding effects of analgesic use.
4.3. Relationship between pain and symptoms of brainstem monoamine
dysfunction
Our third hypothesis was that pain frequency and severity in PD
would correlate with the severity of other symptoms attributable to
serotonergic and norepinephrinergic depletion. Consistent with this,
the severity of autonomic symptoms, anxiety and depression predicted
the severity of pain. A recent study showed no association between pain
severity and the severity of small fibre neuropathy in PD [28], sug-
gesting that central factors may be more important. Although our data
do not enable us to establish a definite cause or direction of this asso-
ciation, we propose that a shared pathophysiology of degeneration in
brainstem monoamine pathways from premotor stages of PD (Braak
stage 2) onwards, contributes to causing autonomic symptoms, affec-
tive symptoms and altered processing of pain in PD.
The results of this study suggest that a major shift in the way we
approach this common and disabling symptom in PD is required. In one
small open study, central pain in PD was reduced by duloxetine [29],
and further studies with this type of medication are clearly warranted,
and should assess effects on the various pain subtypes. Similarly, deep
brain stimulation improved pain in PD, separate from the improvement
in mobility symptoms [30], again stressing the role of central me-
chanisms, distinct from those driving motor impairment.
4.4. Limitations of the study
We acknowledge that there are several limitations to our study
which mean that the results must be interpreted cautiously. The study
population was mainly of early and moderate cases and detailed data on
other comorbidities and analgesic use were not available, so the results
are not necessarily generalisable to all patients with PD. The LANNS
scale while not specifically validated in PD is rated as ‘suggested’ by
experts in PD related pain [31]. Although participants were assessed
ON medication, we did not standardise the timing of assessments with
regards to ON/OFF state and in some cases the pain assessments were
not performed at the same time as other study measures. As with any
large study there is some missing data which could have affected the
results.
We acknowledge that it is possible our results are caused in part by
the type of patients enrolled and the limitations of our methodology.
Other similar studies with different populations and methodologies will
help to clarify this point.
5. Conclusions
The UK Parkinson's Pain Study is the largest and most detailed study
of pain in PD ever performed. Detailed phenotyping and high power
from a large number of participants allowed us for the first time to
explore in detail the factors contributing to subtypes of pain in PD. In
our study population, we found that peripheral factors are not an im-
portant cause of pain in PD, and conclude that central factors are more
important than previously considered.
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